|
|
www.icpermed.eu
| twitter.com/icpermed |
|
Announcement of the 3rd ICPerMed
conference: “Prelude to the Future of Medicine” on
October 5-6, 2022 in Paris |
The International Consortium for
Personalised Medicine is pleased to
invite you to the ICPerMed Conference
“Prelude to the Future of Medicine” on
October 5-6, 2022 in person in Paris,
France. The conference will provide insights
into what the future of medicine will look like by
presenting concrete examples of personalised
medicine approaches and aspects already in
practice. The conference will demonstrate that
implementation of personalised medicine is
progressing through all disciplines and medical
fields and aims to inspire other initiatives to
adopt similar approaches.
Come and learn more about:
- Incorporating patient’s perspective in
personalised healthcare
- The future of personalised medicine in
clinical trials setting
- Challenges in developing health data
governance
- Creating a sustainable innovation
environment for personalised medicine
- Health economic benefits – beyond
cost-effectiveness
Confirmed speakers:
- Laura Navne, The Danish
Centre for Social Science, VIVE, Denmark
- Jillian Hasting-Ward,
Genomics England, UK
- Eyal Zimlichman, Sheba
Medical Center, Israel
- Laura Esserman, University
of California, San Francisco (UCSF), USA
- Markus Kalliola, TEHDAS,
Finland
- Laurent Essioux, Roche,
Switzerland
- Health Data Hub, France
More
about the programme
As space is limited, we encourage you
to register as soon as possible! Fewer than 100
seats are left for onsite
participation.
The registration is free but mandatory (for
virtual or onsite participation). Only the people
registered for the virtual format will receive the
connection access code and only the people
registered for the onsite format will get an
access badge.
Registration
|
back to top
| | |
Save-the date: ICPerMed Training
on “Ethical and Legal Aspects of
Biobanking” |
The International Consortium for Personalised
Medicine has the pleasure to announce the 2nd
ICPerMed Training “Personalised Medicine
Research: Ethical and Legal aspects of Biobanking
and Data Management” which will take
place online in October 2022.
This event aims at training health
professionals and personnel dedicated to
biomedical, technological and scientific research
on the key issues concerning the establishment and
management of a biobank of biological samples and
the data associated with them. The program will
give ample space for practical, organisational and
scientific aspects.
The event will be carried out through lectures
with the participation of external teachers and
leading experts in the sector.
Further information including the exact date of
the training and the registration link will be
published soon on the ICPerMed
website.
|
back to top
| | |
Review: ICPerMed workshop
“Personalised Medicine: How to Ensure Value-based
Implementation” in Brussels, June 21-22,
2022 |
With the “ICPerMed Hybrid Workshop –
Personalised Medicine: How to Ensure Value-based
Implementation” in Brussels and online on
June 21-22, ICPerMed met its partners and
stakeholders in-person after more than two years
of online-only experiences. Despite a national
strike in Belgium and thanks to the hybrid format,
over 50 invited participants joined the workshop.
Besides the ICPerMed Executive Committee
members, the EC representatives, invited
international experts, partners of topic-related
European, national and regional projects as well
as ICPerMed Advisory Board members contributed to
an important and lively discussion. With this
workshop, ICPerMed intended to exchange and find
agreements on the mechanisms and key aspects of
value-based cross cutting effects to guide an
appropriate implementation of personalised
medicine (PM) for the benefits of patients and
citizens.
Carmen Laplaza Santos, Head of Health
Innovation & Ecosystems Unit at the European
Commission, underlined in her opening words that
reflections on health economics and value aspects
are essential for PM development and
implementation, considering also costs that might
appear if PM approaches, e.g. to avoid
inappropriate prescriptions, are not adopted.
The ICPerMed Working Group “Health economic
value of Personalised Medicine” devised the
rationale, its key aspects and organised the
workshop program involving highly renowned experts
for the introductory keynote lectures: Professor
Katherine Payne from the University of Manchester
(UK), provided the audience with an overview of
health economics in relation to PM encompassing
both economic and societal aspects. Afterwards
Chief Scientist Avi Israeli from the Israel
Ministry of Health (IL) and Professor Jennifer
Brooks from the University of Toronto, (CA) talked
about implementation of PM approaches in their
countries.
To stimulate discussions on the second day of
the Workshop Professor Maureen Rutten van Mölken
from the Erasmus University of Rotterdam (NL),
summarised the outcomes and conclusions of the
Coordination and Support Action on Health Economic
Models for Personalised Medicine “HEcoPerMed”.
Finally, a recorded presentation of Professor
Deborah Marshall from the University of Calgary
(CA) emphasised the consideration of non-health
benefits of PM, in particular focusing on patient
perspectives. Further inspiring talks were given
in a session dedicated to the ICPerMed Best
Practice Recognition 2021. Three successful
applicants were invited to Brussels to present
their studies and to participate in the workshop.
The discussions followed in two breakout groups
(online and on-site) covering the following
overall topics:
Personalised medicine
implementation: what should be
addressed?
Key topics in relation to PM implementation
were discussed aiming for the development of
recommendations to appropriately guide
introduction of PM approaches in the different
health care systems. A specific focus was set on
value perspectives.
What will the evolution of the
field mean for society?
As we are moving towards the “generation
genome” and are seeing an increasing accessibility
and interoperability of health data from a
plethora of sources, it was discussed what this
will mean for the evaluation and valuation of PM
approaches for the health care system and public
health approaches more generally.
A report summarising the results of this
ICPerMed Workshop will shortly be published on the
ICPerMed website and will serve as the basis for a
position paper on value aspects of PM to be
published in the first half 2023. |
back to top
| | |
Review: ICPerMed Training on
“Personalised Communication of Personalised
Medicine” |
On June 17, 2022, the first ICPerMed Training
“Personalised Communication in
Personalised Medicine” took place
virtually. More than 50 participants (health
professionals, researchers, citizens and patient
organisations’ representatives) from around the
world participated in this fruitful event. The
training aimed at providing new skills and
comprehensive strategies to communicate in the
personalised medicine (PM) field, in a more
personalised way, especially in the current
crowded informational environment. The first
part of the training included lectures by experts
from the field informing about the following
topics:
- Understanding of the PM field – why specific
communication means are needed in the PM field
(cross sectorial, multinational, etc. – held by
Professor Angela Brand, Maastricht University
- Understanding of the (post)-pandemic
informational space (mainstream media, social
media, infodemia, fake news, influencers etc) –
held by Professor Alina Bârgăoanu, SNSPA, expert
of the European Commission in the field of
disinformation and fake news
- Understanding the role of personalised
communication for the PM environment (ecosystem)
from different perspectives: the citizens,
patients, medical professionals and decision
makers – held by Dr Marius Geantă, Romanian
Centre for Innovation in Medicine
To conclude the first session, examples of best
practices on personalised communication were
presented by Mandana Hasanzad, a member of the
ICPerMed Working Group “Education and
Curricula”.
During the second part of the training, the
participants were split into three parallel
sub-groups (“Citizens”, Patients”, “Healthcare
Professionals”), depending on each participant’s
role and interest. Within these groups, the
question of how to implement personalised
communication in PM in practice was elaborated
together with the experts from the first part of
the training, with a focus on the specific aspects
to be considered when communicating with citizens,
patients and healthcare professionals,
respectively.
The sessions were chaired and moderated by
leading experts in the three fields:
- Professor Christine Chomienne, Vice-Chair of
the Cancer Mission Board I;
- Natacha Bolanos, Head, Membership &
Alliances at Lymphoma Coalition Jacek
Maciejewski (Rak n roll Cancer Charity);
- Mark Lawler, Associate Pro-Vice-Chancellor
and Professor of Digital Health
This online training was one of several
activities of ICPerMed in order to support
research and implementation of PM in Europe and
beyond. |
back to top
| | |
News on the “Best Practice in
Personalised Medicine “ Recognition |
Results of the ICPerMed “Best Practice
in Personalised Medicine“ Recognition (BPR)
2021 During the ICPerMed Workshop
“Personalised Medicine: how to ensure value-based
implementation”on June 21 and 22, 2022 in
Brussels, Ejner Moltzen (ICPerMed Chair) and
Gaetano Guglielmi (Italian Ministry of Health)
have had the pleasure to meet and award a
certificate to two of the three selected BPR 2021
authors, during the Best Practice Recognition
Award Ceremony.
Afterwards the two selected authors Dr Jorge
Simon (Spain) and Dr Juan Josè Beloqui (Spain)
presented their work to the audience. Dr. Jorge
Simon talked about his project entitled
“Alterations in serum glutamate levels are
presented as a new risk factor in Metabolic
associated fatty liver Disease” and Dr. Juan Josè
Beloqui presented the project “PHARMANAGEN”. The
third selected BPR 2021 author is Dr Ludmilla
Thomè Domingos Chinen (Brazil) with her work
entitled “A higher platelet-to-lymphocyte
ratio is prevalent in the presence of circulating
tumour microemboli and is a potential prognostic
factor for non-metastatic colon cancer”.
The selected BPR authors will receive a €500
non-cash support to further disseminate their best
practice examples.
The annual Best Practice Recognition aims at
encouraging and disseminating best practice
examples of implementation in personalised
medicine and at accelerating and maximising the
potential impact of the research findings and
learnings gained on implementation.
ICPerMed Best Practice Recognition 2022
“Data Sharing in Personalised Medicine Clinical
Research” – deadline extension In
order to collect the highest number of best
practice examples, to ensure the maximum
dissemination of the initiative and the widest
space for eligible projects, ICPerMed extends the
deadline for the 2022 Recognition “Data Sharing in
Personalised Medicine Clinical Research” proposal
submission to August 31,
2022. The selected Best Practice
Examples’ authors will be invited to present their
work at the January ICPerMed Workshop 2023, which
will take place in Spain.
Further information
on the call, including the application
form, can be found on the ICPerMed
Webpage. |
back to top
| | |
ICPerMed State of the Art Report
2021 is published |
On June 28, 2022 ICPerMed published its State
of the Art Report 2021. In this report, ICPerMed
presents information about ICPerMed’s past
activities, the upcoming European Partnership for
and activities in the field of personalised
medicine.
In this 2021 state of the art report, ICPerMed
presents its activities (events, ICPerMed
promotion videos, working group activities) of the
past year 2021 and gives the stage to the ICPerMed
Advisory Board to share their view on personalised
medicine, the benefit personalised medicine can
bring to healthcare, healthcare systems and for
patients and citizens, as well as hurdles and
important steps still to be taken to make
personalised medicine a reality for all.
ICPerMed is looking forward to the upcoming
European Partnership for Personalised Medicine, EP
PerMed. In February 2021, ICPerMed published a
concept paper for the future partnership,
developed jointly together with representatives of
ERA PerMed and with support of the European
Commission. The concept paper was discussed in an
open, virtual Information Event "European
Partnership for Personalised Medicine (EP PerMed)
calling for national and regional involvement"
organised by ICPerMed and ERA PerMed on May 31,
2021. In this report, we outline how the
partnership drafting group took over the mandate
to further develop the partnership, the advances
made so far and the next steps until the
(expected) launch in the end of 2023.
ICPerMed is continuously mapping activities in
the field of personalised medicine in order to
promote achievements and successes in research and
implementation as well as to honour activities of
ICPerMed member organisations. A set of currently
running personalised medicine related initiatives
is presented in this 2021 report:
- Two initiatives related to data: TEHDAS and
the SPHN Federated Query System
- Two innovative approaches strengthening the
importance of regions in research and
innovation: Vanguard Initiative and inDemand
- Two national plans working on the
implementation of personalised medicine: IMPaCT
and Mosaic
Download
the report |
back to top
| | |
Update on preparations of the
European Partnership for Personalised Medicine (EP
PerMed) under Horizon Europe |
European Partnerships (EP) are new instruments
of the European Commission (EC) under the Horizon
Europe framework programme, where national and
regional funders join forces, strategies and
budget in defined areas of action. So far, 49 EPs
are foreseen in total and nine of these are in the
Cluster “Health” of Horizon Europe. The European
Partnership for Personalised Medicine, EP PerMed,
is one of the proposed EPs and dedicated to
personalised medicine (PM). Early this year, a draft
proposal for the EP PerMed was already
published by the EC.
When the EP PerMed consortium will be formed, a
proposal will be drafted and submitted to the EC.
The expected total budget for 7-10 years by the
Member States and the EC will be over 300 Mio.
Euros. Besides joint transnational calls (JTC)
dedicated to PM research, other activities are
planned, like events, strategic publications,
communication platforms, demonstration pilots
and/or surveys.
The basis of these activities, described in the
proposal and put into action during the EP PerMed
runtime (~2023-2033), will be the Strategic
Research and Innovation Agenda (SRIA), which is
currently in preparation.
All European Partnerships have to develop a
SRIA before their launch in order to ensure that
their long-term vision is translated into concrete
roadmaps with smart and measurable objectives. In
general, all EPs aim at implementing the topics,
actions and activities identified in the
respective SRIA. According to the EC, the SRIAs
should include:
- A well-developed intervention logic with
concrete objectives and targeted impact,
measurable expected outcomes, deliverables and
milestones within a defined timeframe, and the
resources and foreseen portfolio of activities
to match those.
- A monitoring framework for assessing
progress towards the objectives, including
corresponding Key Performance Indicators, should
be defined using SMART criteria: Specific,
Measurable, Attainable, Relevant, Time-bound.
- Plans for updating the SRIA, including
future possible involvement and consultations of
the stakeholders (openness & transparency;
flexibility in implementation).
To this end, the EP PerMed Drafting Group aims
to identify gaps, needs and challenges which
should be addressed and overcome in the areas
“research”, “innovation systems” and
“implementation” to foster PM for the benefit of
patients and citizens. Information will be
gathered through different means from all related
areas and sectors important for PM: Strategic
documents from various stakeholders will be
consulted, a dedicated event as well as a public
online consultation will be organised. By
interviewing experts and stakeholders that are
active in the area of PM, the EP PerMed Drafting
Group seeks to add further input to this
information collection.
The next important steps in 2022 for the
preparation of the EP PerMed are:
- The development of a Personalised Medicine
Strategic Research and Innovation Agenda (PM
SRIA) in the course of 2022.
- The publication of the call for the
co-funded European Partnership for Personalised
Medicine end of 2022.
The EP PerMed proposal submission will take
place in 2023 and the partnership is supposed to
be launched by the end of 2023.
For any question around the EP PerMed,
please contact the EP PerMed drafting group.
Contact details: eppermed@dlr.de
|
back to top
| | |
Update on ERA PerMed – Joint
Transnational Call 2022 and ERA PerMed
Newsletter |
5th ERA PerMed Joint Transnational
Call (JTC2022): The 5th ERA
PerMed Joint Transnational Call (JTC2022) for
research projects in personalised medicine on the
topic “Prevention in Personalised Medicine” had
the support of 33 funding organisations. The call
was launched on December 1, 2021, having the
French National Research Agency (ANR) as Joint
Call Secretariat (JCS), with the support of the
Spanish National Health Institute Carlos III
(ISCIII). The available budget for this call is 29
Mio € (approx.).
With its fifth Transnational Call, ERA PerMed
fosters research and innovation activities for the
development of tailor-made strategies for
prevention of disease and disease progression, at
three different levels: 1. Preventive measures
decreasing the rate of incidence (primary
prevention), 2. Early detection to increase the
efficacy of a preventive therapy, even before
symptoms are developed (secondary prevention), and
3. Interventions preventing disease recurrence or
improving patients’ care and quality of life
(tertiary prevention).
173 pre-proposals were
submitted in the pre-proposal phase for a total of
more than 193 M€ requested funds.
60 consortia were invited to submit a
full-proposal until June 14, 2022. The Peer Review
Panel will take place in Paris on September 6-7,
2022 in order to provide a final ranking list
after the full-proposals’ evaluation phase.
8th ERA PerMed
Newsletter: The 8th ERA PerMed
Newsletter will be launched in
July 2022 and will contain statistics on the ERA
PerMed JTC2021 funded projects and other news and
updates related to ERA PerMed and personalised
medicine related initiatives.
For further information about ERA PerMed,
please refer to the ERA PerMed
website and the ERA PerMed Twitter account @ERANET_PerMed.
|
back to top
| | |
News from the ICPerMed-related
Coordination and Support Actions |
PROPHET – a
PeRsOnalized Prevention roadmap for the future of
HEalThcare”: information on the Coordination and
Support Action
PROPHET - a PeRsOnalized Prevention roadmap for
the future HEalThcare" will develop a Strategic
Research and Innovation Agenda (SRIA) for
Personalised Prevention, in order to support the
implementation of innovative, sustainable and
effective personalised programmes to prevent
common chronic diseases. Technological biomedical
advances (including omics data and digital tools)
make risk stratification at the individual level
possible. However, development of Personalised
Prevention approaches must be accompanied by
healthcare system transition, including citizen
engagement, healthcare professional education and
addressing organisational, social and legal
issues. PROPHET will be centred around stakeholder
engagement and the SRIA co-creation process in
relation to three main strands of activities:
Mapping, Assessment, and Building. Firstly, the
consortium will summarise, evaluate and discuss
with the relevant stakeholders the extent to which
all these new technologies can synergise
(Mapping). Secondly, it will design a holistic
framework (the PROPHET Framework) that will
include all the necessary aspects to appraise
Personalised Prevention approaches and their
adoption by Public Health Authorities
(Assessment). Thirdly, PROPHET will support the
introduction of Personalised Prevention Programmes
by providing guidelines for their design, engaging
with healthcare professionals (especially those
working with policy makers), and increasing health
literacy at the population level on the benefits
of Personalised Prevention (Building). PROPHET
will liaise with other key current and forthcoming
initiatives at EU level, such as ICPerMed, the
European Partnership (EP) on Personalised Medicine
(EP PerMed), the CSA Beyond 1 Million Genomes
(B1MG), and the EP on Transforming Health and Care
Systems. The consortium consists of 18
beneficiaries and 2 affiliated entities across 12
EU Countries, and a large number of stakeholders
already engaged from different Target
Groups. |
back to top |
EU-Africa PerMed –
First webinar on oncology and publication of new
project outcomes
On May 17, EU-Africa PerMed organised the
webinar “Oncology: Personalised Medicine
approach”, the 1st of a series of webinars and
training activities with the objective to support
the translation of personalised medicine research
into practice and to create networks between
European and African researchers. Around 50-60
participants of 31 countries, from the African
region: Benin, Burundi, Cameroon, Costa d'Ivoire,
Egypt, Ethiopia, Gambia, Ghana, Kenya, Mali,
Morocco, Nigeria, Rwanda, Senegal, Sierra Leone,
South Africa, Sudan, Tanzania, Togo, Tunisia and
Zimbabwe as well as participants from Europe and
North America, followed presentations focussing on
cancer as a major public health problem worldwide.
After a short introduction of the EU-Africa
PerMed project and an introductory note on ethical
governance of personalised medicine research,
including a discussion on why we need patient
participation in research, the following talks
focussed on oncology diseases. Cancer presents
intra- and inter-population unique phenotypes and
is expected to surpass infectious disease as the
leading cause of mortality in Africa within the
next two decades. Particularly, the Black
populations are having a high morbidity and
mortality for most types. At large, the prevention
and personalised treatment of cancers have been
driven by the understanding of the genetic make-up
of the disease of mostly non-African populations.
Therefore, there is the needed to address this
knowledge gap to understand the underlying genetic
causes of and genomic alterations associated with
cancer among black Africans. If you
missed the event, the recording is available:
Watch
video on YouTube
Stay tuned! Our next ONLINE training
events:
- Personalised Medicine Ethics and
Regulations in Africa. Series of Online
Webinars. From Principles to Practice, organised
by the Institut de Recherche en Santé, de
Surveillance Epidemiologique et de Formations,
in September and October 2022
- Start-ups & Personalised
Medicine, organised by the African
Population & Health Research Centre, in
November 2022
The first in-person event / Summer School on
Clinical studies in Personalised Medicine will be
organised in South Africa (January-February
2023).
The EU-Africa PerMed project furthermore
processed the substantial input provided by the
African stakeholders during the first Stakeholder
Workshop in February. The results are available in
the form of:
One major outcome of the first stakeholder
workshop was the need to start collaboration and
reflections in Africa in the field of personalised
medicine on the regional level: North, South,
East, West and Central Africa. Hence, EU-Africa
PerMed is planning regional workshops, at least
one in each region, starting with an East African
regional meeting, that will take place on 13-14
July 2022, in Nairobi, Kenya, hosted by NACOSTI.
Additionally, the EU-Africa PerMed is excited to
bring together the project consortium on July 12
for the first in-person meeting since its launch
in 2021.
Follow EU-Africa PerMed:
|
back to top |
IC2PerMed: Roadmap
validation Workshop
On June 9-10, 2022 Università Cattolica del
Sacro Cuore, leader of the European funded
project IC2PerMed coordinated by Professors Walter
Ricciardi and Stefania Boccia, hosted an
international stakeholder workshop in Rome. The
workshop aimed at gathering opinions and comments
from experts and partners regarding the first
version of the IC2PerMed Roadmap. Over 40
stakeholders with interdisciplinary background, in
presence and online, joined from over 10 countries
to discuss and provide inputs aimed at
implementing personalised medicine between Europe
and China. The event brought to light the
following activities: on the one hand,
- the results of the mapping activities
(started in 2020) related to policies, research
programs, and innovative approaches addressed to
personalised medicine in the EU and China
- the outputs obtained from the consultation
and discussion held at the numerous workshops
organised by partners over the previous two
years.
The integration of these activities resulted in
a first version of the Roadmap, which presented in
a concise and narrative manner the elaboration of
priorities, identified by the experts as essential
for a shared development of personalised medicine
between Europe and China. The discussion,
organised over two days, benefited from the inputs
provided by the methodological description of the
activities but also from several lectures given by
prominent European and Chinese personalised
medicine research leaders. Integrations and
comments received from the experts enriched and
improved the preliminary work produced on the
Roadmap to flow into a more precise and effective
product. The goal of this project is being
able to pave the way for a solid collaboration
that can prove fruitful scientifically and
industrially for both realities. |
back to top |
PERMIT: The PERMIT
project has come to an end, but it is only the
beginning for the PERMIT
recommendations
On June 16 and 17, 2022, the members and
associated partners of the PERMIT consortium, as
well as personalised medicine (PM) experts and
other invested stakeholders met in Milan (and
online) at the Istituto di Recherche
Farmacologiche Mario Negri for the final meeting
of the project. After 2.5 years of successful
collaboration, the recommendations on the full
personalised medicine research pipeline were
presented and discussed, along with the
dissemination, implementation and sustainability
plan for the months and years to come.
A presentation on the upcoming European
Partnership for Personalised Medicine
contributed to a rich discussion on the
opportunities for the application of the PERMIT
recommendations, while a panel discussion on the
regulatory context for personalised medicine
research, highlighted the challenges that lie
ahead in this rapidly evolving field. The
importance of having a sustained multi-stakeholder
dialogue was highlighted by all, as an essential
element to continue fostering robust and
reproducible personalised medicine research.
The PERMIT recommendations will be disseminated
through publications, lay summaries and several
series of training materials, all available
through the PERMIT
project website.
|
back to top |
Sino-EU PerMed:
Save The Date for the 1st Sino-EU Permed Science
& Technology Webinar
“Perspectives in Personalised Medicine: genomics,
rare diseases, devices”
The Science & Technology Webinar on
“Perspectives in Personalised Medicine: genomics,
rare diseases, devices” is planned for
September 13, 2022 08:00 – 13:00
CEST. Details will be available on the Sino-EU
PerMed Website soon and will also be shared
via social media. |
back to top |
EULAC PerMed: 4th
EULAC PerMed Summer School “Clinical studies on
Personalised Medicine” on November 15-16,
2022 |
|
The 4th EULAC PerMed Summer School “Clinical
studies on Personalised Medicine” will take place
on November 15 and 16, 2022 at the Wyndham All
Brook Hotel in Panama City, Panama. The course is
planned as hybrid event. Depending on the pandemic
situation, it could be 100 % virtual. Applications
are possible from July 7 to September 1,
2022.
This summer school is open for up to 25 young
researchers from both Europe and LAC regions to
facilitate the exchange of information and
strategies about gaps and challenges in clinical
studies related to personalised
medicine. |
During the two days researchers and experts on
clinical studies working in different fields will
offer a landscape of the clinical studies in LAC
countries and in the EU. Some projects funded
within the ERA-Net Cofund for Personalised
Medicine (ERA PerMed) will be illustrated as
example of international collaboration. The
participation is free of charge and selected
participants will receive an economic support for
their physical participation. Priority is given to
participants from LAC countries. Further
information including the announcement, the agenda
and information on the application process can be
found here.
|
|
back to top
| | |
Facts: |
- ICPerMed started in November 2016
- 49 funding organisations
- 29 countries
- 5 Working Groups: Clinical Studies in Personalised
Medicine, Personalised Medicine in healthcare, Patients’
empowerment, Education & Curricula in Personalised
Medicine, Health economic value of Personalised Medicine
ICPerMed is also represented on Twitter and
LinkedIn. Follow us on Twitter! @ICPerMed
Follow us on LinkedIn! @ICPerMed
- The International Consortium for Personalised Medicine
| |
| |